Product logins

Find logins to all Clarivate products below.


Regional Forecast is an add on offering from Clarivate’s Company & Drugs (C&D) that renders extended coverage of existing C&D proprietary data. With increasing demand to analyze the data in much granularity, market forecasters can now have an in-depth analysis of the data which is now available for different segments (such as therapy area, drug group and drug class) across multiple regions (U.S., Europe, Japan and Others).

Data is readily accessible in the form of downloadable reports / interactive dashboard which enables the user to navigate and analyze the data quickly and easily. Data is covered for fourteen therapeutic areas mentioned below:

  • Anti-Infectives
  • Cardiovasculars
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Genitourinary
  • Hematology
  • Metabolism
  • Musculoskeletal Pain
  • Oncology
  • Ophthalmology
  • Respiratory
  • Transplant
  • Vaccines
     

User Guidelines:

1.Dashboard has three tabs – ‘Regional Data’, ‘Base Year Analysis’ and ‘Forecast Analysis’

    a.‘Regional Data’ tab details the regional level sales for individual drug classes consolidated at  

        drug group and therapy area levels

    b.‘Base Year Analysis’ tab enables the user to quickly analyze and compare sales at drug

        class and drug group levels

    c.‘Forecast Analysis’ tab enables the user to assess the forecast     

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2024
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…
Report
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2024
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Ovarian Cancer | Disease Landscape & Forecast | G7 | 2024
The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and…
Report
Systemic Lupus Erythematosus – Geographic Focus: China – China In-Depth – Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs or systems in the body. The treatment goals of physicians who manage SLE patients differ depending on…
Report
Urticaria | Disease Landscape & Forecast | G7 | 2024
The urticaria drug market is dominated by oral medications—including steroids and second-generation, nondrowsy antihistamines—which are prescribed for both chronic inducible urticaria (CIndU)…